Lifeward CMO granted 15,000 RSUs in Form 4

Rose Keith Dale reported acquisition or exercise transactions in this Form 4 filing.

Rhea-AI Filing Summary

Rose Keith Dale reported acquisition or exercise transactions in this Form 4 filing.

Lifeward Ltd. reported that Chief Medical Officer Rose Keith Dale received an equity award of 15,000 ordinary shares in the form of restricted stock units. The RSUs were granted on May 1, 2026 under the company’s 2025 Incentive Compensation Plan.

The RSUs vest in four equal annual installments starting on the grant date, meaning a portion becomes deliverable each year over four years as long as vesting conditions are met. Following this award, Dale is shown as beneficially owning 17,083 ordinary shares directly.

Insider Trade Summary

Grant/Award: 15,000 shares

Grant/Award 1 txn

Insider Rose Keith Dale

Role Chief Medical Officer

Type	Security	Shares	Price	Value
Grant/Award	Ordinary Shares, no par value per share	15,000	$0.00	$0.00

Holdings After Transaction: Ordinary Shares, no par value per share — 17,083 shares (Direct)

Footnotes (1)

1. F1. Represents 15,000 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on May 1, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal annual installments commencing from the Grant Date.

Key Figures

RSU grant size: 15,000 shares Grant price: $0.00 per share Post-grant holdings: 17,083 shares +1 more

4 metrics

RSU grant size 15,000 shares Restricted stock units granted May 1, 2026

Grant price $0.00 per share Equity compensation, not open-market purchase

Post-grant holdings 17,083 shares Ordinary shares beneficially owned after transaction

Vesting schedule Four equal annual installments RSUs vest ratably from May 1, 2026 grant date

Key Terms

restricted stock units, 2025 Incentive Compensation Plan, vest ratably

3 terms

restricted stock units financial

"issuable upon the vesting of restricted stock units ("RSUs") granted on May 1, 2026"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

2025 Incentive Compensation Plan financial

"RSUs granted on May 1, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan"

vest ratably financial

"The RSUs vest ratably in four equal annual installments commencing from the Grant Date"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Lifeward (LFWD) report for Rose Keith Dale?

Lifeward reported that Chief Medical Officer Rose Keith Dale received 15,000 restricted stock units. These RSUs represent ordinary shares granted as equity compensation under the 2025 Incentive Compensation Plan and increase her directly owned position to 17,083 ordinary shares after the award.

How many Lifeward (LFWD) shares were granted in this Form 4 filing?

The filing shows a grant of 15,000 ordinary shares in the form of restricted stock units. These RSUs were awarded at an indicated price of $0.00 per share as equity compensation rather than a market purchase, under Lifeward’s 2025 Incentive Compensation Plan.

How do the Lifeward (LFWD) RSUs granted to Rose Keith Dale vest?

The 15,000 restricted stock units vest in four equal annual installments. Vesting commences on the May 1, 2026 grant date, so one-quarter of the award becomes deliverable each year for four years, assuming continued satisfaction of the plan’s vesting conditions.

What is Rose Keith Dale’s share ownership after this Lifeward (LFWD) award?

After the reported RSU grant, Rose Keith Dale is shown as beneficially owning 17,083 ordinary shares directly. This figure reflects her position immediately following the award disclosed in the Form 4 and provides context for the size of the new equity grant.

Was the Lifeward (LFWD) RSU grant to Rose Keith Dale a market purchase?

No. The 15,000 ordinary shares were granted as restricted stock units at $0.00 per share. This indicates a compensation-related award under the 2025 Incentive Compensation Plan rather than an open-market stock purchase by the Chief Medical Officer.

What plan governs the Lifeward (LFWD) RSU grant reported in this Form 4?

The RSU grant was made under Lifeward’s 2025 Incentive Compensation Plan. This plan provides for equity-based compensation, and the filing notes that the 15,000 restricted stock units granted on May 1, 2026 will vest ratably over four years from the grant date.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 05/20/2026 - 08:15 AM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Rose Keith Dale

(Last) (First) (Middle)

C/O LIFEWARD LTD.

2 CABOT ROAD

(Street)

HUDSON MASSACHUSETTS 01749

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Lifeward Ltd. [ LFWD ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Chief Medical Officer

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
05/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Ordinary Shares, no par value per share	05/01/2026		A		15,000(1)	A	$0	17,083	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents 15,000 ordinary shares, no par value per share, issuable upon the vesting of restricted stock units ("RSUs") granted on May 1, 2026 (the "Grant Date") under the Issuer's 2025 Incentive Compensation Plan. The RSUs vest ratably in four equal annual installments commencing from the Grant Date.

	/s/ Almog Adar, as Attorney-in-Fact	05/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)